comprehensive -WSS

comprehensive

author：fashion 2025-09-30 12:17:16 - browse：657

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Flu, Covid vaccination rates decline, new survey data show

focus

WSS

Flu, Covid vaccination rates decline, new survey data show

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Weight bias in eating disorder treatment complicated by new weight loss drugs

Medicare innovation center doesn’t save money, experts say

WHO recommends second malaria vaccine

2023 Nobel Prize in Medicine goes to Karikó and Weissman

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why we need to separate burnout from moral injury in health care

Medical records are filled with copy

Why are elite athletes different? Take a look at their microbes

Jerome Adams on the need for new antivirals for Covid

New guidelines on severe brain injury complicate already difficult decisions

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The science behind Janet Jackson's pregnancy at 49

Continuity nursing helped my family in our darkest PICU moments

The Karikó problem: Lessons for funding basic research

focus

Cloning humans is technically possible. It's curious no one has tried

Congress extends some pandemic preparedness programs

Setback for rare diseases as Taysha Gene Therapies pulls back

The strategy behind pharma's lawsuits over drug pricing reform

CDC concerned about possible undetected monkeypox spread in U.K.

What we owe ALS patients — and why one company fell short

entertainment

focus

explore

knowledge